|
Mar 7
|
Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results
|
|
Mar 7
|
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript
|
|
Mar 6
|
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
|
|
Jan 17
|
Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%
|
|
Jan 16
|
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
|
|
Dec 7
|
Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year
|
|
Dec 6
|
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
|
|
Nov 30
|
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
|
|
Nov 29
|
Adaptimmune Receives Transfer of IND for Lete-cel Program
|
|
Nov 13
|
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Nov 13
|
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript
|
|
Nov 9
|
Forecast: Analysts Think Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Business Prospects Have Improved Drastically
|
|
Nov 8
|
Adaptimmune Reports Third Quarter Financial Results and Business Update
|
|
Nov 8
|
Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
|
|
Nov 7
|
Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing
|
|
Oct 31
|
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
|
|
Oct 31
|
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
|
|
Aug 9
|
Adaptimmune Reports Second Quarter Financial Results and Business Update
|